Clinical trial

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

NCT06090266

Study summary

ClinicalTrials.gov

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention OR502 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cemiplimab Normalized identity: cemiplimab View linked drug · Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-10-24

PhasePHASE1 / PHASE2

Conditions

Cancerverified · MONDO: cancer

Tumor, Solidunresolved

Malignant Neoplasmverified · MONDO: cancer

Metastatic Cancerverified · MONDO: metastatic malignant neoplasm

Advanced Solid Tumorunresolved

Cutaneous Melanomaverified · MONDO: cutaneous melanoma

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

OR502DRUG

CemiplimabDRUG · verified · RxNorm: cemiplimab

Sponsors & collaborators

OncoResponse, Inc.lead sponsor

Mapped research locations

San AntonioTexas, United States1 AustinTexas, United States1 FairfaxVirginia, United States1 IrvingTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06090266 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.